22UA logo

BioNTech BUL:22UA Stock Report

Last Price

€110.00

Market Cap

€24.0b

7D

0%

1Y

n/a

Updated

13 Nov, 2024

Data

Company Financials +

22UA Stock Overview

A biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.

22UA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis


BioNTech SE Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioNTech
Historical stock prices
Current Share PriceUS$110.00
52 Week HighUS$110.60
52 Week LowUS$77.15
Beta0.26
11 Month Change0%
3 Month Changen/a
1 Year Changen/a
33 Year Changen/a
5 Year Changen/a
Change since IPO-57.53%

Recent News & Updates

Recent updates

Shareholder Returns

22UABG BiotechsBG Market
7D0%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how 22UA performed against the BG Biotechs industry.

Return vs Market: Insufficient data to determine how 22UA performed against the BG Market.

Price Volatility

Is 22UA's price volatile compared to industry and market?
22UA volatility
22UA Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in BG Market0%
10% least volatile stocks in BG Market0%

Stable Share Price: 22UA's share price has been volatile over the past 3 months compared to the BG market.

Volatility Over Time: Insufficient data to determine 22UA's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20086,133Ugur Sahinwww.biontech.de

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors.

BioNTech SE Fundamentals Summary

How do BioNTech's earnings and revenue compare to its market cap?
22UA fundamental statistics
Market cap€24.01b
Earnings (TTM)-€466.90m
Revenue (TTM)€3.04b

7.9x

P/S Ratio

-51.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
22UA income statement (TTM)
Revenue€3.04b
Cost of Revenue€476.90m
Gross Profit€2.56b
Other Expenses€3.03b
Earnings-€466.90m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

May 05, 2025

Earnings per share (EPS)-1.95
Gross Margin84.31%
Net Profit Margin-15.36%
Debt/Equity Ratio0%

How did 22UA perform over the long term?

See historical performance and comparison